オーストラリアTGA/2017 ARCS Annual Conferenceの講演資料
8/30付でオーストラリアTGAから「TGA presentations: 2017 ARCS Annual Conference, 22-24 August 2017」と題して、TGAによる講演資料が掲載されています。
掲載資料(リンクが張られています)は以下の通りです。
●Session A01 : The Australian and International landscape - keynote forum
●Session A07 : Pharmacovigilance - the Australian landscape
●Session A09 : A spotlight on other reforms from the medicines and medical devices regulation review
Regulatory reforms at the Therapeutic Goods Administration (TGA)
●Session A11 : GMP clearance requirements for medicines manufactured overseas
●Session A12 : Spotlight on medical device MMDR reforms
●Session A14 : The Australian Pharmacovigilance Inspection Program
●Session A17 : Conformity assessment evidence
●Session A18 : A journey to better medicine labels - an update on TGO 92
●Session A25 : Spotlight on complementary medicines MMDR reforms
●Session A26 : Increasing post-market vigilance requirements for medical devices
●Session A28 : The role of the patient in pharmacovigilance
●Session B03 : Supply and distribution of therapeutic goods
●Session B11 : Bioequivalence
●Sessions B13/B20 : Online Clinical Trial Notification (CTN)
●Session B18 : Spotlight on prescription medicines reforms
Spotlight on prescription medicine post-market reforms
●Session B19 : Clinical evidence guidelines
●Session C02 : Earlier access to medicines and medical technologies and the Medicine and Medical Device Regulatory Review
興味のあるものがあれば、下記URLのウェブサイト内の講演タイトルからダウンロードしてください。
https://www.tga.gov.au/tga-presentations-2017-arcs-annual-conference-22-24-august-2017
掲載資料(リンクが張られています)は以下の通りです。
●Session A01 : The Australian and International landscape - keynote forum
●Session A07 : Pharmacovigilance - the Australian landscape
●Session A09 : A spotlight on other reforms from the medicines and medical devices regulation review
Regulatory reforms at the Therapeutic Goods Administration (TGA)
●Session A11 : GMP clearance requirements for medicines manufactured overseas
●Session A12 : Spotlight on medical device MMDR reforms
●Session A14 : The Australian Pharmacovigilance Inspection Program
●Session A17 : Conformity assessment evidence
●Session A18 : A journey to better medicine labels - an update on TGO 92
●Session A25 : Spotlight on complementary medicines MMDR reforms
●Session A26 : Increasing post-market vigilance requirements for medical devices
●Session A28 : The role of the patient in pharmacovigilance
●Session B03 : Supply and distribution of therapeutic goods
●Session B11 : Bioequivalence
●Sessions B13/B20 : Online Clinical Trial Notification (CTN)
●Session B18 : Spotlight on prescription medicines reforms
Spotlight on prescription medicine post-market reforms
●Session B19 : Clinical evidence guidelines
●Session C02 : Earlier access to medicines and medical technologies and the Medicine and Medical Device Regulatory Review
興味のあるものがあれば、下記URLのウェブサイト内の講演タイ
https://www.tga.gov.au/tga-
コメント
/
/
/
コメント